Literature DB >> 9935049

Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG.

K Sakata1, M Shirotani, H Yoshida, C Kurata.   

Abstract

UNLABELLED: Sympathetic overactivity has been noted in various clinical stages of essential hypertension. The purpose of this study is to investigate 123I-metaiodobenzylguanidine (MIBG) uptake and washout in patients with borderline and mild hypertension.
METHODS: To assess cardiac sympathetic function in essential hypertension, we performed 123I-MIBG cardiac imaging and echocardiography in 25 normotensive, 25 borderline hypertensive and 24 mildly hypertensive men. Age and body mass index were similar in the three groups.
RESULTS: Regarding the echocardiographic variables, the left ventricular mass index (LVMI) was significantly higher in the mildly hypertensive group (125.6+/-28.6 g/m2) than in the normotensive (99.9+/-20.7 g/m2) and the borderline hypertensive (110.0+/-24.4 g/m2) groups (P < 0.001 and P < 0.05, respectively). Regarding the scintigraphic variables, the heart-to-mediastinum (H/M) ratio was significantly lower in the mildly hypertensive group (1.8+/-0.3) than in the normotensive (2.1+/-0.3) and the borderline hypertensive (2.1+/-0.2) groups. In contrast, the washout rate was significantly higher in the mildly hypertensive group (17.6%+/-10.8%) than in the normotensive (7.0%+/-4.9%) and the borderline (11.9%+/-8.9%) hypertensive groups (P< 0.001 and P< 0.02, respectively). In addition, the borderline hypertensive group had a significantly higher washout rate than the normotensive group (P < 0.05). MIBG washout rate had a strong positive correlation with LVMI (r = 0.77, P < 0.0001). In contrast, the H/M ratio had a weak negative correlation with LVMI (r = -0.40, P < 0.0006).
CONCLUSION: During the course of establishment of essential hypertension, the washout rate becomes higher with the advance of hypertension and with the development of left ventricular hypertrophy. Thus, we suggest a strong relationship between cardiac sympathetic activity and the advance of hypertension at its early stages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935049

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Homocysteine levels are associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients.

Authors:  Futoshi Anan; Hidetoshi Yonemochi; Takayuki Masaki; Naohiko Takahashi; Mikiko Nakagawa; Nobuoki Eshima; Tetsunori Saikawa; Hironobu Yoshimatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-04       Impact factor: 9.236

2.  Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio.

Authors:  Kenichi Nakajima; Kosuke Matsubara; Takehiro Ishikawa; Nobutoku Motomura; Ryo Maeda; Nasima Akhter; Koichi Okuda; Junichi Taki; Seigo Kinuya
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

3.  Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients.

Authors:  Tetsuji Shinohara; Naohiko Takahashi; Kunio Yufu; Futoshi Anan; Tetsuya Kakuma; Masahide Hara; Mikiko Nakagawa; Tetsunori Saikawa; Hironobu Yoshimatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-01       Impact factor: 9.236

4.  The role of impaired sympathetic nerve function in enhancing coronary vasoconstriction in patients with hypertrophic cardiomyopathy.

Authors:  Shinro Matsuo; Tetsuya Matsumoto; Ichiro Nakae; Minoru Horie
Journal:  Exp Clin Cardiol       Date:  2007

5.  Abdominal visceral fat accumulation is associated with the results of (123)I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients.

Authors:  Futoshi Anan; Takayuki Masaki; Hidetoshi Yonemochi; Naohiko Takahashi; Mikiko Nakagawa; Nobuoki Eshima; Tetsunori Saikawa; Hironobu Yoshimatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-06       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.